Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer

Authors: Aaron S Mansfield, Paivi S Heikkila, Ari T Vaara, Karl AJ von Smitten, Jukka M Vakkila, Marjut HK Leidenius

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

There is evidence that the immune systems of patients with breast cancer are dysfunctional. Regulatory T cells (Tregs), and IDO, an immunosuppressive enzyme, are associated with more advanced disease in some cancers and may promote immunologic tolerance to tumors. Our aim was to assess whether expression of Foxp3, a marker of Tregs, and IDO were linked with nodal metastasis in breast cancer patients. Inhibitors of IDO are available and could potentially demonstrate utility in breast cancer if IDO drives progression of disease.

Methods

Sentinel lymph nodes (SLN) of 47 breast cancer patients with varying degrees of nodal disease and 10 controls were evaluated for expression of Foxp3 and IDO using immunohistochemistry. Positively stained cells were quantified and their distribution within the SLN noted.

Results

The proportion of Foxp3+ cells was higher in SLN of cancer patients than controls (19% v. 10%, p < 0.001). Specifically, there were more Foxp3+ cells in SLN with metastasis than tumor-free SLN (20% v. 14%, p = 0.02). The proportion IDO+ cell in SLN of cancer patients was not statistically different than controls (4.0% v. 1.6%, p = 0.08). In order to demonstrate the combined immunosuppressive effect of Foxp3 and IDO, we categorized each SLN as positive or negative for Foxp3 and IDO. The Foxp3+/IDO+ group almost exclusively consisted of cancer patients with node positive disease.

Conclusion

In conclusion, our study shows that Foxp3+ cells are associated with more advanced disease in breast cancer, a finding that is proving to be true in many other cancers. As IDO has been found to promote differentiation of Tregs, IDO may become a suitable target to abrogate the development of T-cell tolerance and to promote an effective immune response to breast cancer. Our results about the combined expression of IDO and Foxp3 in metastastic SLN support this assumption.
Appendix
Available only for authorised users
Literature
1.
Shevach EM: CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002, 2 (6): 389-400.PubMed
2.
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10 (9): 942-949. 10.1038/nm1093.CrossRefPubMed
3.
Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C: The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005, 11 (23): 8326-8331. 10.1158/1078-0432.CCR-05-1244.CrossRefPubMed
4.
Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003, 9 (12): 4404-4408.PubMed
5.
Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999, 163 (10): 5211-5218.PubMed
6.
Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004, 114 (2): 280-290.CrossRefPubMedPubMedCentral
7.
Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL: Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999, 189 (9): 1363-1372. 10.1084/jem.189.9.1363.CrossRefPubMedPubMedCentral
8.
Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998, 281 (5380): 1191-1193. 10.1126/science.281.5380.1191.CrossRefPubMed
9.
Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ: Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002, 101 (2): 151-155. 10.1002/ijc.10645.CrossRefPubMed
10.
Sakurai K, Amano S, Enomoto K, Kashio M, Saito Y, Sakamoto A, Matsuo S, Suzuki M, Kitajima A, Hirano T, et al: [Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer]. Gan To Kagaku Ryoho. 2005, 32 (11): 1546-1549.PubMed
11.
Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, et al: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006, 12 (4): 1144-1151. 10.1158/1078-0432.CCR-05-1966.CrossRefPubMed
12.
Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini V, Bonanno G, Rutella S, Durelli I, et al: Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 2007, 109 (7): 2871-2877.PubMed
13.
Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH: Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007, 67 (2): 792-801. 10.1158/0008-5472.CAN-06-2925.CrossRefPubMed
14.
Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP: Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980, 45 (12): 2917-2924. 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M.CrossRefPubMed
15.
Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S: Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol. 1989, 7 (9): 1239-1251.PubMed
16.
Mansour EG, Ravdin PM, Dressler L: Prognostic factors in early breast carcinoma. Cancer. 1994, 74 (1 Suppl): 381-400.CrossRefPubMed
17.
Leidenius MH, Krogerus LA, Toivonen TS, von Smitten KA: Sentinel node biopsy is not sensible in breast cancer patients with large primary tumours. Eur J Surg Oncol. 2005, 31 (4): 364-368. 10.1016/j.ejso.2004.11.006.CrossRefPubMed
18.
Whiteside TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006, 16 (1): 3-15. 10.1016/j.semcancer.2005.07.008.CrossRefPubMed
19.
Sobin LHWC, editors: TNM classification of malignant tumors. 2002, New York: John Wiley and Sons, 6
20.
Leidenius MH, Krogerus LA, Toivonen TS, Von Smitten KJ: The feasibility of intraoperative diagnosis of sentinel lymph node metastases in breast cancer. J Surg Oncol. 2003, 84 (2): 68-73. 10.1002/jso.10296.CrossRefPubMed
21.
Leikola JP, Toivonen TS, Krogerus LA, von Smitten KA, Leidenius MH: Rapid immunohistochemistry enhances the intraoperative diagnosis of sentinel lymph node metastases in invasive lobular breast carcinoma. Cancer. 2005, 104 (1): 14-19. 10.1002/cncr.21133.CrossRefPubMed
22.
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006, 24 (34): 5373-5380. 10.1200/JCO.2006.05.9584.CrossRefPubMed
23.
Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F: Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res. 2008, 14 (8): 2413-2420. 10.1158/1078-0432.CCR-07-4491.CrossRefPubMed
24.
Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L: Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004, 173 (2): 1444-1453.CrossRefPubMed
25.
Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihiro K, Toge T: Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer. 2006, 106 (6): 1227-1236. 10.1002/cncr.21729.CrossRefPubMed
26.
Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR: The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol. 2008, 181 (8): 5396-5404.CrossRefPubMedPubMedCentral
27.
Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F: Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun. 2008, 375 (3): 331-335. 10.1016/j.bbrc.2008.07.156.CrossRefPubMedPubMedCentral
28.
Yu G, Dai H, Chen J, Duan L, Gong M, Liu L, Xiong P, Wang CY, Fang M, Gong F: Gene delivery of indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses. J Gene Med. 2008, 10 (7): 754-761. 10.1002/jgm.1201.CrossRefPubMed
29.
Park MJ, Min SY, Park KS, Cho YG, Cho ML, Jung YO, Park HS, Chang SH, Cho SG, Min JK, et al: Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis Res Ther. 2008, 10 (1): R11-10.1186/ar2361.CrossRefPubMedPubMedCentral
30.
Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S: Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 2007, 98 (6): 874-881. 10.1111/j.1349-7006.2007.00470.x.CrossRefPubMed
31.
Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, Kaempgen E, Schrama D, Becker JC: Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother. 2007, 56 (7): 1017-1024. 10.1007/s00262-006-0256-1.CrossRefPubMed
32.
Sharma MD, Baban B, Chandler P, et al: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007, 117 (9): 2570-82. 10.1172/JCI31911.CrossRefPubMedPubMedCentral
33.
Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, McCormick D, Jager MJ, Cree IA: Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer. 2007, 96 (12): 1879-1887. 10.1038/sj.bjc.6603763.CrossRefPubMedPubMedCentral
34.
Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, Essner R: Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res. 2005, 11 (1): 107-112.PubMed
Metadata
Title
Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer
Authors
Aaron S Mansfield
Paivi S Heikkila
Ari T Vaara
Karl AJ von Smitten
Jukka M Vakkila
Marjut HK Leidenius
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-231

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

B7-H4gene polymorphisms are associated with sporadic breast cancer in a Chinese Han population

Research article

High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression

Research article

Triple negative breast carcinoma is a prognostic factor in Taiwanese women

Research article

Mutation analysis of the AATF gene in breast cancer families

Research article

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines

Research article

Knowledge, attitudes and practice of breast cancer screening among female health workers in a Nigerian urban city
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits